Family Medicine Commons^™

Teaming Together To Care For Our Deaf Patients: Insights From The Deaf Health Clinic, Kate Panzer, Junghyun Park, Leslie Pertz, Michael M. Mckee

JADARA

Deaf patients often struggle with accessing culturally competent care. Poor communication and inaccessible health information negatively impact Deaf individuals, resulting in poorer health outcomes and inappropriate health care use. To address this problem, the Family Medicine Department established the Deaf Health Clinic in 2015 through the efforts of healthcare providers fluent in American Sign Language. After that, the clinic faced several management issues, and implemented strategies to address them. The paper discusses lessons learned and suggests potential and tested solutions to reduce gaps in health care for Deaf individuals.

Career Regret Among Physician Assistants: A Comparative Survey Of Primary And Specialty Care Careers, Talia Sierra, Jennifer Forbes, Michael Nelson

Internet Journal of Allied Health Sciences and Practice

Purpose: This study investigated if career regret varies among physician assistants (PAs) practicing in primary and specialty care fields. This information may assist practicing and aspiring physician assistants when selecting or changing their career path.

Methods: A survey was emailed to 5,000 primary and specialty care physician assistants. Items indicating career regret were compared between primary and specialty care groups.

Results: Eight hundred and thrity-four (16.7%) completed surveys were received back. Career regret is similar between primary and specialty care physician assistants, with low reports from both groups. No statistical significance was found between primary care and specialty care groups …

A Comparison Of Various Monoclonal Antibodies To The Previous Standard Of Care Chemotherapy In The Treatment Of Advanced-Stage Melanoma, Kevin Verde, Lauren Johnson, Alex Clancy, Ashley Goldberg, Aleia Monden, Priya Philip

Internet Journal of Allied Health Sciences and Practice

In the year 2015, it is estimated that the number of new cases of invasive melanoma will be 42,670 in males and 31,200 in females.¹ Melanoma is treatable with early diagnosis; however, more advanced disease has devastating outcomes. For the past decade, two chemotherapy agents, dacarbazine and temozolomide, have been the treatment of choice for advanced stage III or IV melanoma requiring systemic treatment. Interleukin-2 (IL-2) therapy has been used but with serious side effects. More recently, the focus has shifted to monoclonal antibodies and enzyme inhibitors as the main systemic treatment for advanced cutaneous melanoma. This literature review …